Novartis' (NVS) omalizumab meets all primary and secondary endpoints in a pivotal Phase 3 study...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis' (NVS) omalizumab meets all primary and secondary endpoints in a pivotal Phase 3 study in patients with chronic spontaneous urticaria. The study is the second of three pivotal trials designed to test the efficacy and safety of the treatment. The drug — which, if approved for the new indication, would be the only treatment available for the condition outside of antihistamines — is being developed with Genentech (RHHBY.OB). NVS +0.86% premarket. (PR)